Rationale for the use of aldosterone antagonists in congestive heart failure

Drugs
Ricardo Rocha, G H Williams

Abstract

Traditionally, the role of aldosterone in heart failure was thought to be a result of its effects on epithelial cells where it induces sodium reabsorption and potassium excretion with subsequent haemodynamic effects from intravascular volume expansion. On this basis, spironolactone, a non-selective aldosterone antagonist, has been used for the treatment of congestive heart failure to block aldosterone-mediated effects in epithelial cells. The Randomized Aldactone Evaluation Study (RALES), in which spironolactone was added to existing therapy in patients with heart failure, showed a significant reduction in morbidity and mortality. These results suggest that the role of aldosterone in the pathophysiology of cardiovascular disease may be more complex than previously recognised. There now is extensive experimental and growing clinical evidence for an important physiological role for aldosterone in the pathology of cardiac and renal disease. Classical effects of aldosterone are mediated via its nuclear receptor. Novel non-epithelial effects of aldosterone are mediated via a second messenger system, which involves activation of the sodium/hydrogen antiporter. These effects of aldosterone have been demonstrated in the kidney, vascula...Continue Reading

References

Dec 1, 1990·Circulation Research·C G BrillaK T Weber
Jan 1, 1983·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·P BiffignandiG M Molinatti
Dec 1, 1981·The Journal of Endocrinology·J StaessenA Amery
Jan 1, 1980·Current Medical Research and Opinion·A G Smith
Dec 1, 1994·Cardiovascular Research·M J Fullerton, J W Funder
Jul 1, 1994·Journal of Molecular and Cellular Cardiology·C G BrillaK T Weber
Dec 15, 1995·Cell·D J MangelsdorfR M Evans
Mar 1, 1996·European Journal of Endocrinology·J W Funder
Aug 1, 1996·Cardiovascular Research·M E UllianT A Morinelli
Jan 1, 1997·Hypertension·Y TakedaR Takeda
Aug 1, 1997·Endocrinology·C E Gomez-SanchezE P Gomez-Sanchez
Mar 28, 1998·The Journal of Biological Chemistry·J S SilvestreC Delcayre
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·G Fejes-TóthA Náray-Fejes-Tóth
Apr 16, 1998·Cardiovascular Research·C E Gómez-Sánchez
Feb 19, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M NishimuraG Kimura
Dec 11, 1999·Circulation Research·J P Bénitah, G Vassort
Mar 22, 2000·Circulation Research·A S MihailidouH H Rasmussen
Nov 18, 2000·Circulation·R Roberts, K Schwartz
Jul 18, 2001·The Journal of Clinical Investigation·X Y WangM A Knepper
Jul 21, 2001·Hypertension·F C Luft, A Busjahn
Jan 1, 1964·American Journal of Surgery·J W CONNR M NESBIT
Sep 1, 1942·The Journal of Clinical Investigation·D C Darrow, H C Miller

❮ Previous
Next ❯

Citations

May 12, 2004·Molecular and Cellular Endocrinology·John D BaxterPaul Webb
May 12, 2004·Molecular and Cellular Endocrinology·Amy E RudolphEllen G McMahon
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·William F Young
Apr 20, 2004·Assay and Drug Development Technologies·Chang BaiLeonard P Freedman
Apr 26, 2003·Heart Disease·Domenic A Sica
Dec 15, 2006·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Katrin KlicheHans Oberleithner
Sep 20, 2012·Endocrinology·Rongqin RenJohn A Cidlowski
Mar 11, 2008·Journal of Hypertension·Gian Paolo RossiAnthony M Heagerty
Nov 15, 2007·Current Cardiology Reports·Richard J Auchus, Fiemu E Nwariaku
Feb 16, 2005·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Paul W M FedakRen-Ke Li
Apr 22, 2009·Expert Opinion on Drug Metabolism & Toxicology·James A MuldowneyCassandra D Benge
Oct 31, 2003·Expert Opinion on Investigational Drugs·W H Wilson Tang, Gary S Francis
May 2, 2003·Expert Opinion on Investigational Drugs·Henry Krum, Danny Liew
Apr 9, 2016·Methodist DeBakey Cardiovascular Journal·Domenic A Sica
Oct 20, 2009·The Surgical Clinics of North America·Travis J McKenzieGeoffrey B Thompson
Jun 19, 2009·The Journal of Clinical Hypertension·Samira Ubaid-GirioliHeitor Moreno
May 7, 2010·Journal of Veterinary Pharmacology and Therapeutics·P OvaertT Bardon
Aug 11, 2006·International Journal of Cardiology·Valerie GodfreyAllan D Struthers
Jul 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Martha A ZeigerUNKNOWN American Association of Endocrine Surgeons
Dec 14, 2004·The Annals of Pharmacotherapy·Brian J Barnes, Patricia A Howard
Aug 21, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Roland CoppensJacob C Easaw
Jan 17, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Joseph FrancisRobert B Felder
Aug 22, 2003·Cardiovascular Drug Reviews·Charles T Stier
Feb 18, 2003·Current Opinion in Nephrology and Hypertension·Richard J Auchus
Dec 1, 2010·Hormone Molecular Biology and Clinical Investigation·Rongqin Ren, John A Cidlowski
Jan 6, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Katherine F Croom, Caroline M Perry
Feb 3, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Steven G CocaGregory K Buller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.